Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

550 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A pivotal role for Mcl-1 in Bortezomib-induced apoptosis.
Podar K, Gouill SL, Zhang J, Opferman JT, Zorn E, Tai YT, Hideshima T, Amiot M, Chauhan D, Harousseau JL, Anderson KC. Podar K, et al. Among authors: harousseau jl. Oncogene. 2008 Jan 31;27(6):721-31. doi: 10.1038/sj.onc.1210679. Epub 2007 Jul 23. Oncogene. 2008. PMID: 17653083
Mcl-1 and Bcl-xL are co-regulated by IL-6 in human myeloma cells.
Puthier D, Derenne S, Barillé S, Moreau P, Harousseau JL, Bataille R, Amiot M. Puthier D, et al. Among authors: harousseau jl. Br J Haematol. 1999 Nov;107(2):392-5. doi: 10.1046/j.1365-2141.1999.01705.x. Br J Haematol. 1999. PMID: 10583232 Free article.
Multiple myeloma.
Dalton WS, Bergsagel PL, Kuehl WM, Anderson KC, Harousseau JL. Dalton WS, et al. Among authors: harousseau jl. Hematology Am Soc Hematol Educ Program. 2001:157-77. doi: 10.1182/asheducation-2001.1.157. Hematology Am Soc Hematol Educ Program. 2001. PMID: 11722983 Review.
The evolving background for high-dose treatment for myeloma.
Sirohi B, Powles R, Harousseau JL, Anderson KC. Sirohi B, et al. Among authors: harousseau jl. Bone Marrow Transplant. 2007 Dec;40(12):1097-100. doi: 10.1038/sj.bmt.1705867. Epub 2007 Oct 1. Bone Marrow Transplant. 2007. PMID: 17906702 Review.
Management of treatment-emergent peripheral neuropathy in multiple myeloma.
Richardson PG, Delforge M, Beksac M, Wen P, Jongen JL, Sezer O, Terpos E, Munshi N, Palumbo A, Rajkumar SV, Harousseau JL, Moreau P, Avet-Loiseau H, Lee JH, Cavo M, Merlini G, Voorhees P, Chng WJ, Mazumder A, Usmani S, Einsele H, Comenzo R, Orlowski R, Vesole D, Lahuerta JJ, Niesvizky R, Siegel D, Mateos MV, Dimopoulos M, Lonial S, Jagannath S, Bladé J, Miguel JS, Morgan G, Anderson KC, Durie BG, Sonneveld P. Richardson PG, et al. Among authors: harousseau jl. Leukemia. 2012 Apr;26(4):595-608. doi: 10.1038/leu.2011.346. Epub 2011 Dec 23. Leukemia. 2012. PMID: 22193964 Review.
Efficacy and safety of bortezomib in patients with renal impairment: results from the APEX phase 3 study.
San-Miguel JF, Richardson PG, Sonneveld P, Schuster MW, Irwin D, Stadtmauer EA, Facon T, Harousseau JL, Ben-Yehuda D, Lonial S, Goldschmidt H, Reece D, Bladé J, Boccadoro M, Cavenagh JD, Neuwirth R, Boral AL, Esseltine DL, Anderson KC. San-Miguel JF, et al. Among authors: harousseau jl. Leukemia. 2008 Apr;22(4):842-9. doi: 10.1038/sj.leu.2405087. Epub 2008 Jan 17. Leukemia. 2008. PMID: 18200040 Clinical Trial.
The retinoblastoma susceptibility gene RB-1 in multiple myeloma.
Juge-Morineau N, Harousseau JL, Amiot M, Bataille R. Juge-Morineau N, et al. Among authors: harousseau jl. Leuk Lymphoma. 1997 Jan;24(3-4):229-37. doi: 10.3109/10428199709039011. Leuk Lymphoma. 1997. PMID: 9156653 Review.
550 results